News

Check out these important stories we covered this past week.

A new virtual program aims to train clinicians and other providers on terminology and how to engage patients in effective dialogue and counseling.

The submission is for a fourth dose of its Spikevax (mRNA-1273) vaccine in adults 18 years of age and older.

Policies keep case counts down even when vaccination rates are low, new analysis finds.

A study of over 8 million participants found no correlation between COVID-19 vaccination and developing neurological conditions. However, a risk of some neurological conditions was increased after COVID-19 infection.

A recent JAMA article discussed the role of caregiver vaccination status in pediatric hospitals and ethics of exclusion.

A Tufts University research time identified a novel testing method to detect Lyme disease reinfection and successful treatment.

Engaging in antimicrobial stewardship programs led to a reduction in antibiotic usage in long-term care facilities, potentially reducing the growing risk of antibiotic resistance.

Pfizer’s COVID-19 pill Paxlovid, which includes nirmatrelvir and ritonavir, reduced the risk of hospitalization and death by 89% among adults at high risk for severe disease, recently published phase 2/3 trial data show.

The study authors suggest further research and investment to identify areas of support for individuals at the highest risk of poor outcomes.

The application is based on 2 Israeli studies for the additional shot for people 65 years and older.

In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.

Axcella Therapeutics chief medical officer Dr. Margaret Koziel discusses the stage 2a clinical trial for their novel long covid treatment.

This study comes just weeks after the company announced another HIV vaccine trial.

In a case series of 18 patients, all but 3 were cured by single-donor fecal microbiota transplantation capsule therapy.

The new COVID-19 sub-variant, called “Deltacron” or “Stealth Omicron,” appears to be the most contagious strain yet. However, this does not necessarily mean there will be a dramatic spike in cases.

In a nationally televised interview, Pfizer Albert Bourla said it is necessary to fend off waning protection.

Findings of JAMA Network Open analysis reveal effects of interventions designed to prevent spread.

The first study of COVID-19 vaccination status among romantic couples found 15.63% were in disagreement over whether to receive the vaccine.

“Deltacron,” a COVID-19 strain with genes from both the Delta and Omicron variants, appears to have been circulating since the beginning of the year.

The war on Ukraine is expected to drive COVID-19 and other infectious diseases, meaning health organizations and neighboring countries should prepare to assist in the impending health crises.

Popular pain and fever-reducing drugs can have unintended consequences when it comes to infectious diseases.

The retroviral HIV drug HERV-K could be effectively repurposed to treat patients with meningioma and acoustic neuroma, common primary brain tumors.

First-in-class triaminopyrimidine demonstrates antimalarial efficacy in first-in-human test of dosing, kinetics, and clearing parasite in infected volunteers.

Patients hospitalized during the COVID-29 pandemic for unrelated conditions were 20% more likely to die than in the prepandemic period.

The phase 3 results for its antibiotic, cefepime-taniborbactam, demonstrated it met its primary endpoint and the company says it is on track for a fourth quarter 2022 FDA NDA.

The product is designed to eliminate some of the drawbacks of fecal microbiota transplantation.

Using real-time genetic surveillance, investigators found bacterial infections rapidly develop resistance to antibiotics, only to have these gene mutations disappear within a few days of switching to a different treatment.

A large surveillance study of 2 symptom-reporting databases found side effects after Moderna or Pfizer-BioNTech COVID-19 vaccination were frequently nonserious and resolved within 1-2 days.

The company is examining its antiviral pill for children 6 to 17 years of age in combating COVID-19.